205 related articles for article (PubMed ID: 31994465)
1. Outwitting an Old Neglected Nemesis: A Review on Leveraging Integrated Data-Driven Approaches to Aid in Unraveling of Leishmanicides of Therapeutic Potential.
Kwofie SK; Broni E; Dankwa B; Enninful KS; Kwarko GB; Darko L; Durvasula R; Kempaiah P; Rathi B; Miller Iii WA; Yaya A; Wilson MD
Curr Top Med Chem; 2020; 20(5):349-366. PubMed ID: 31994465
[TBL] [Abstract][Full Text] [Related]
2. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
3. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
[TBL] [Abstract][Full Text] [Related]
4. Computational Identification of Chemical Compounds with Potential Activity against Leishmania amazonensis using Nonlinear Machine Learning Techniques.
Castillo-Garit JA; Flores-Balmaseda N; Álvarez O; Pham-The H; Pérez-Doñate V; Torrens F; Pérez-Giménez F
Curr Top Med Chem; 2018; 18(27):2347-2354. PubMed ID: 30499402
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis drug discovery: recent progress and challenges in assay development.
Zulfiqar B; Shelper TB; Avery VM
Drug Discov Today; 2017 Oct; 22(10):1516-1531. PubMed ID: 28647378
[TBL] [Abstract][Full Text] [Related]
6. Advancement in leishmaniasis diagnosis and therapeutics: An update.
Kumari D; Perveen S; Sharma R; Singh K
Eur J Pharmacol; 2021 Nov; 910():174436. PubMed ID: 34428435
[TBL] [Abstract][Full Text] [Related]
7. Insights into the drug screening approaches in leishmaniasis.
Gopu B; Kour P; Pandian R; Singh K
Int Immunopharmacol; 2023 Jan; 114():109591. PubMed ID: 36700771
[TBL] [Abstract][Full Text] [Related]
8. Drug search for leishmaniasis: a virtual screening approach by grid computing.
Ochoa R; Watowich SJ; Flórez A; Mesa CV; Robledo SM; Muskus C
J Comput Aided Mol Des; 2016 Jul; 30(7):541-52. PubMed ID: 27438595
[TBL] [Abstract][Full Text] [Related]
9. Anti-leishmanial Nanotherapeutics: A Current Perspective.
Shah A; Gupta SS
Curr Drug Metab; 2019; 20(6):473-482. PubMed ID: 30360732
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of New Cyclic Imides Derived from Safrole, Structure- and Ligand-based Approaches to Evaluate Potential New Multitarget Agents Against Species of Leishmania.
de Sousa Luis JA; da Silva Costa NA; Luis CCS; Lira BF; Athayde-Filho PF; de Souza Lima TK; da Câmara Rocha J; Scotti L; Scotti MT
Med Chem; 2020; 16(1):39-51. PubMed ID: 31208311
[TBL] [Abstract][Full Text] [Related]
11. Conventional Versus Natural Alternative Treatments for Leishmaniasis: A Review.
Passero LFD; Cruz LA; Santos-Gomes G; Rodrigues E; Laurenti MD; Lago JHG
Curr Top Med Chem; 2018; 18(15):1275-1286. PubMed ID: 30277153
[TBL] [Abstract][Full Text] [Related]
12. Insights into the current status of privileged N-heterocycles as antileishmanial agents.
Razzaghi-Asl N; Sepehri S; Ebadi A; Karami P; Nejatkhah N; Johari-Ahar M
Mol Divers; 2020 May; 24(2):525-569. PubMed ID: 31028558
[TBL] [Abstract][Full Text] [Related]
13. An update on small molecule strategies targeting leishmaniasis.
Kapil S; Singh PK; Silakari O
Eur J Med Chem; 2018 Sep; 157():339-367. PubMed ID: 30099256
[TBL] [Abstract][Full Text] [Related]
14. Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease.
Sharlow ER; Grögl M; Johnson J; Lazo JS
Mol Interv; 2010 Apr; 10(2):72-5. PubMed ID: 20368366
[No Abstract] [Full Text] [Related]
15. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
Borsari C; Jiménez-Antón MD; Eick J; Bifeld E; Torrado JJ; Olías-Molero AI; Corral MJ; Santarem N; Baptista C; Severi L; Gul S; Wolf M; Kuzikov M; Ellinger B; Reinshagen J; Witt G; Linciano P; Tait A; Costantino L; Luciani R; Tejera Nevado P; Zander-Dinse D; Franco CH; Ferrari S; Moraes CB; Cordeiro-da-Silva A; Ponterini G; Clos J; Alunda JM; Costi MP
Eur J Med Chem; 2019 Dec; 183():111676. PubMed ID: 31542713
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to discover marine antileishmanial natural products.
Tempone AG; Martins de Oliveira C; Berlinck RG
Planta Med; 2011 Apr; 77(6):572-85. PubMed ID: 21243582
[TBL] [Abstract][Full Text] [Related]
18. Novel Synthetic Approaches for Bisnaphthalimidopropyl (BNIP) Derivatives as Potential Anti-Parasitic Agents for the Treatment of Leishmaniasis.
Keskin E; Ucisik MH; Sucu BO; Guzel M
Molecules; 2019 Dec; 24(24):. PubMed ID: 31888250
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase 1B as a target against leishmaniasis.
D'Annessa I; Castelli S; Desideri A
Mini Rev Med Chem; 2015; 15(3):203-10. PubMed ID: 25769969
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
